Calyx originates from the Greek word ‘kalyptein’ that refers to a bud that grows into a flower. Since, 1979 Calyx Chemicals and Pharmaceuticals has been growing in the Anti-Tubercular, Macrolide, and Anti-malarial segment of APIs.
We have been in the pharmaceutical space over the last 4 decades and enjoy a pioneering position in some of the product offerings.
Our philosophy has been to serve the markets for acute therapies which are widely prevalent over the world especially in India.
The company was one the first standalone API manufacturers of Indian origin to have regulatory accreditations from the USFDA, EDQM, and WHO PQ to name a few.
Calyx At An Inflection Point Driven By The Increased Demand
For Regulatory Compliant Facility
- WHO-Geneva Inspected
- US FDA inspection and facility acceptance
- WHO – Geneva inspection & Facility acceptance
- US FDA inspection and facility acceptance
- WHO – Geneva inspection & Facility acceptance
- Patents filed for FTF molecules
- US FDA inspection and facility acceptance
- Outstanding exports performance award - 2012 from Pharmexcil
- 100+ strength of R&D team
- Green chemistry being worked on select APIs
- EQDM Approval
- WHO-Geneva Inspected
- ISO 9001:2008 & Korean FDA acceptance
- US FDA inspection and facility acceptance
- Silver Award for Quality Excellence from IDMA
- Partnered with Clinton Foundation for Malaria
- New State-of-the-Art R&D Centre approved by DSIR
- Established US office
- Entry in to Anti – Malaria
- EDQM approval
- US FDA inspected
- First US – FDA acceptance and R&D centre at Dombivli
- WHO Geneva acceptance
- Commencement of Tarapur production facility
